CSIMarket
 
Monte Rosa Therapeutics Inc   (GLUE)
Other Ticker:  
 
 
Price: $6.4100 $0.32 5.255%
Day's High: $6.8 Week Perf: 3.05 %
Day's Low: $ 6.09 30 Day Perf: 34.66 %
Volume (M): 289 52 Wk High: $ 8.83
Volume (M$): $ 1,851 52 Wk Avg: $5.68
Open: $6.09 52 Wk Low: $2.44



 Market Capitalization (Millions $) 319
 Shares Outstanding (Millions) 50
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -133
 Cash Flow (TTM) (Millions $) -54
 Capital Exp. (TTM) (Millions $) 25

Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutics targeting protein degradation pathways. The company aims to harness the body's natural protein degradation system to selectively eliminate disease-causing proteins, potentially leading to the development of novel treatments for various diseases including cancer and genetic disorders. Monte Rosa Therapeutics utilizes its proprietary platform technology to discover and optimize small molecules that can degrade specific proteins, offering a unique approach to drug development.


   Company Address: 321 Harrison Avenue Boston 2118 MA
   Company Phone Number: 949-2643   Stock Exchange / Ticker: NASDAQ GLUE
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Unleashing the Potential: Monte Rosa Therapeutics Takes on Inflammatory Diseases with MRT-8102, a Molecular Glue Degrader and Pathway Inhibitor

Published Mon, Mar 11 2024 11:00 AM UTC

Monte Rosa Therapeutics Initiates IND Enabling Studies for MRT-8102: A Groundbreaking Molecular Glue Degrader and NLRP3/IL-1 Pathway InhibitorMonte Rosa Therapeutics, a leading biopharmaceutical company, has recently announced the initiation of Investigational New Drug (IND) enabling studies for their groundbreaking compound, MRT-8102. This novel drug is a first-in-class NEK...

Management Announcement

Monte Rosa Therapeutics Forges Ahead with Ambitious Milestones Despite Recent Stock Drops

Published Mon, Jan 8 2024 12:15 PM UTC



Monte Rosa Therapeutics, a leading biotechnology company specializing in the development of novel small molecule therapies, recently provided a comprehensive corporate update, highlighting its key anticipated milestones for the year 2024. However, the company's shares experienced a decline of -2.21% over the past five trading days, signaling an underlying concern a...

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Inc unveils groundbreaking Q3 2023 earnings: Discover the future of Biotech & Pharma

Monte Rosa Therapeutics Inc (NASDAQ: MRNA) has experienced a strong gain in its stock price over the past five trading days, recording a solid increase of 6.34%. Meanwhile, the stock of GLUE (GlycoMimetics) has faced a decline of -21.99% over the last month. Furthermore, Monte Rosa Therapeutics Inc's stock is currently trading on the NASDAQ exchange at a significant -44.4% below its 52-week average.
Shareholders of GLUE did not anticipate any changes in the company's top-line performance during the reporting season from July to September 30, 2023. However, there are concerns among investors regarding the company's operating deficit, which amounted to $-36.968 million during the same period. Although GLUE has not announced its revenue figures yet, it is helpful to compare recent revenue with its performance in the third quarter of 2022. At that time, GLUE reported an operating deficit of $-28.362 million.

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Inc witnesses soaring working expenditures, fueling success in the latest fiscal period

The Biotechnology & Pharmaceuticals sector has been closely monitoring the second quarter of 2023 results, with particular focus on the operating shortfall of $-37.221 million from GLUE. Although GLUE has not provided any information about its top-line performance for the April to June 2023 quarter, it is worth noting that the operating shortfall has improved compared to the second quarter of 2022 when it stood at $-27.231 million.
However, market analysts are eagerly anticipating whether Monte Rosa Therapeutics Inc (MRTI) will provide some positive news regarding its top-line. Companies in the biotech and pharmaceutical industry often undergo periods of fluctuating performance as they strive to establish successful revenue sources. The most recent fiscal period has witnessed a considerable increase in net losses, reaching $-35.178 million.
Investors and industry players can expect the next financial report from Monte Rosa Therapeutics Inc to be released on November 9, 2023, providing further insight into the company's performance and potential future strategies.
In terms of market performance, it is noteworthy that Monte Rosa Therapeutics Inc shares have experienced a decline of -2.61% in the past seven days. This brings the year-to-date performance to a negative growth of -13.62%. Currently, the company's shares are trading on the NASDAQ at a value -9.7% below its 52-week average.

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Inc Reports Disappointing Q1 2023 Results with a net loss of $-117 million and a negative ROE; Operating loss of $-34.259 million raises concerns

Monte Rosa Therapeutics Inc (MRNA) has reported a cumulative net loss of $-117 million for the 12 months ending in the first quarter of 2023. This resulted in a negative return on equity (ROE) of -42.09%, which was lower than 83 other players in the Biotechnology & Pharmaceuticals industry. The overall ranking for ROE has improved from a total ranking of 3322 in the fourth quarter of 2022 to 2468 currently.
Shareholders were not surprised by the business's lack of growth during the January to March 31, 2023 reporting cycle. However, they were concerned about the operating loss of $-34.259 million during the same period. Monte Rosa Therapeutics Inc has not yet released its revenue figures, but an analysis of their operations in the first quarter of 2022 shows an operating loss of $-24.302 million.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com